Sandoz has launched a generic paclitaxel formulation. It is the first generic of Abraxis BioScience’s (a Bristol Myers Squibb Co.) Abraxane to be approved by the Food and Drug Administration.

Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...

The long haul of regulatory issues at Cipla's Goa manufacturing site had resulted in multiple delays for Abraxane's anticipated launch, prompting analysts to project it as a potential opportunity only ...

However, with the widespread use of BMS, two notable complications emerged ... Some drugs, such as paclitaxel, can be coated directly on a metal stent, whereas the majority of the drugs need ...

Roche meanwhile is running the IMpassion131 trial of Tecentriq plus paclitaxel versus paclitaxel ... s $12 billion sales in 2019. Bristol-Myers Squibb published the abstract from its CheckMate ...

The European Commission has cleared the use of PD-L1 inhibitor Tecentriq (atezolizumab) alongside Celgene’s Abraxane (nab-paclitaxel ... s Keytruda and Bristol-Myers Squibb’s Opdivo however ...

The arrival of DESs was seen as the third revolution in interventional cardiology, after balloon angioplasty and BMS. These initial ... agents such as sirolimus or paclitaxel.

The data hint at sirolimus becoming a useful option or even a replacement for paclitaxel, but full 5-year follow-up is needed.